NY-ESO-1 Antibody (6A146): sc-71734

NY-ESO-1 Antibody (6A146) is a mouse monoclonal IgG1 antibody that detects NY-ESO-1 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). NY-ESO-1, also known as the autoimmunogenic cancer/testis antigen, plays a crucial role in the immune response against tumors, making NY-ESO-1 a significant target for cancer immunotherapy. NY-ESO-1 is primarily expressed in the testis and ovary, which is important because such restricted normal tissue distribution minimizes the risk of autoimmunity while allowing for robust immune responses in cancer patients. NY-ESO-1 (6A146) antibody frequently detects proteins associated with strong antibody and CD8+ T cell responses, particularly against HLA-A2-restricted epitopes, highlighting NY-ESO-1′s potential as a therapeutic target. NY-ESO-1′s ability to elicit both humoral and cellular immune responses underscores NY-ESO-1′s importance in the development of effective cancer treatments, as NY-ESO-1 can stimulate the immune system to recognize and attack tumor cells expressing this antigen. With unique immunogenic properties and limited expression in normal tissues, anti-NY-ESO-1 antibody (6A146) serves as an invaluable tool for researchers exploring cancer immunology and developing novel therapeutic strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

NY-ESO-1 Antibody (6A146) References:

1. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.  |  Robbins, PF., et al. 2011. J Clin Oncol. 29: 917-24. PMID: 21282551
2. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.  |  Endo, M., et al. 2015. Mod Pathol. 28: 587-95. PMID: 25412843
3. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.  |  Robbins, PF., et al. 2015. Clin Cancer Res. 21: 1019-27. PMID: 25538264
4. NY-ESO-1 as a diagnostic and prognostic marker for myxoid liposarcoma.  |  Jo, U., et al. 2022. Am J Transl Res. 14: 1268-1278. PMID: 35273728
5. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.  |  Liu, X., et al. 2022. J Immunother Cancer. 10: PMID: 35338087
6. Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma.  |  Hashimoto, K., et al. 2022. Eur J Histochem. 66: PMID: 35736245
7. Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors.  |  Hashimoto, K., et al. 2023. Medicine (Baltimore). 102: e33908. PMID: 37266606
8. Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment.  |  Zhou, H., et al. 2023. Front Immunol. 14: 1255799. PMID: 37731507
9. NY-ESO-1 antigen-antibody interaction process based on an TFBG plasmonic sensor.  |  Qu, H., et al. 2023. Biomed Opt Express. 14: 5921-5931. PMID: 38021116
10. The role of the NY-ESO-1 in the prognosis of gastric cancer.  |  Misir, Z., et al. 2023. Biomol Biomed. 24: 813-820. PMID: 38153439

The preferred NY-ESO-1 antibody is NY-ESO-1 Antibody (E978): sc-53869.